Pacira BioSciences, Inc. (PCRX)

Market Cap	948.08M
Revenue (ttm)	716.79M
Net Income (ttm)	21.44M
Shares Out	44.93M
EPS (ttm)	0.47
PE Ratio	44.77
Forward PE	5.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	980,653
Open	21.83
Previous Close	21.85
Day's Range	20.64 - 21.98
52-Week Range	16.00 - 27.64
Beta	0.25
Analysts	Buy
Price Target	32.40 (+53.56%)
Earnings Date	Nov 6, 2025

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 790
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Analyst Summary

According to 5 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price target is $32.4, which is an increase of 53.56% from the latest price.

Price Target

$32.4

(53.56% upside)

Analyst Consensus: Buy